FARN:LON
Faron Pharmaceuticals Oy
36,60 GBX
arrow_upward
+0,27%(+0,100) 1 д.
12.10, 16:30:00 ч. Гринуич+1 · GBX
search
Всички символи
| Символ | Цена | Промяна | % промяна |
|---|
insights_autoГенерира се водещата статистика за FARN…
Отваряне
35,06 GBX
Висока
38,00 GBX
Ниска
35,00 GBX
Пазарна кап.
74,16 млн.
Ср. обем
42,63 хил.
Обем
7,06 хил.
Най-висока цена за 52 седм.
193,58 GBX
Най-ниска цена за 52 седм.
34,00 GBX
EPS
-0,10 GBX
Акции в обращение
31,03 млн.
Брой служители
36
Отваряне
35,06 GBX
Висока
38,00 GBX
Ниска
35,00 GBX
Пазарна кап.
74,16 млн.
Ср. обем
42,63 хил.
Обем
7,06 хил.
Най-висока цена за 52 седм.
193,58 GBX
Най-ниска цена за 52 седм.
34,00 GBX
EPS
-0,10 GBX
Акции в обращение
31,03 млн.
Брой служители
36
Новинарски материали
От източници в мрежата и новинарски партньори
Investor.bg
·
преди 3 дни
Dow Jones добави над 400 пункта, подкрепен от технологичния сектор
marketscreener.com
·
преди 18 минути
S&P 500 index showed little change after Stockholm Stock Exchange close
Yahoo Finance
·
преди 55 минути
What Does VEON (NASDAQ:VEON) Satellite To Mobile Launch Mean For Bangladesh?
BeInCrypto
·
преди 39 минути
Citi Says S&P 500 Needs AI and Non-AI Stocks to Reach 8,100
Профил
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Всичко за Faron Pharmaceuticals Oy
Главен изпълнителен директорМарку Ялканен
Служители36
Дата на основаване2003
Централен офис-
Бранш-
Уебсайтfaron.com